Showing posts with label gray matter. Show all posts
Showing posts with label gray matter. Show all posts

Monday, November 10, 2008

Multiple Sclerosis Progression Can Be Predicted With MRI





ScienceDaily (Nov. 6, 2008) — A new study published in Journal of Neuroimaging shows that MRI scans used on multiple sclerosis (MS) patients to determine if the disease has affected gray matter in the brain can identify those at-risk for progression of disability.

MS affects approximately 400,000 people in the United States and as many as 2.5 million worldwide. It is the most common cause of progressive disability in young adults. While the cause of the disease remains unknown, it is characterized by damage to the covering over the nerve fibers in the brain and spinal cord, or to the nerve fiber itself.

In an attempt to understand the causes of disease progression, researchers at the Partners MS Center, led by Dr. Rohit Bakshi and his team, have developed new ways to detect gray matter damage.

Dr. Bakshi, Director of the Laboratory for Neuroimaging Research and an Associate Professor of Neurology and Radiology at the Brigham and Women's Hospital and Harvard Medical School, led a four year follow-up study, which found that patients with unnatural darkness of gray matter structures as seen on MRI pictures carried a higher risk for progression of physical disability. This abnormal darkness is referred to as T2 hypointensity, and is suggestive of excessive iron deposits. In addition, the researchers found that the new marker of gray matter damage showed closer correlations with patients' clinical status than other established MRI markers of disease severity, including lesions, also known as "plaques," and shrinkage of the brain, also know as "atrophy."

"MRI scans obtained from patients with MS are being used to develop measures and techniques that can accurately measure the visible and hidden damage to the brain, especially in gray matter areas and can more accurately predict the course of the disease," says Bakshi.

As a result of the findings, MRI-based measurement of gray matter damage may be used as a surrogate marker of disease progression. Physicians may therefore be able to more accurately identify patients at risk for developing this progressive disease.

MS has been traditionally viewed as a disease affecting the white matter of the brain, where messages are transferred between the brains gray matter sections, which control the processing of information. While prior research has shown that the brain's gray matter is also affected, studies detailing its effects have been limited. In addition, current therapies for MS are incomplete, raising the need to better understand disease mechanisms and the biomarkers of disease progression. If excessive iron in gray matter contributes to damage, this would open a new avenue for developing better therapies.

Journal reference:

1. Neema et al. Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis. Journal of Neuroimaging, 2008; DOI: 10.1111/j.1552-6569.2008.00296.x

Adapted from materials provided by Wiley-Blackwell, via EurekAlert!, a service of AAAS.
Need to cite this story in your essay, paper, or report? Use one of the following formats:
APA

MLA
Wiley-Blackwell (2008, November 6). Multiple Sclerosis Progression Can Be Predicted With MRI. ScienceDaily. Retrieved November 10, 2008, from http://www.sciencedaily.com­ /releases/2008/11/081105164308.htm

Friday, October 05, 2007

Thalamic atrophy associated with cognitive impairment in MS





Source: Reuters

Date: Thu, 4 October 2007

Thalamic volume is lower in multiple sclerosis (MS) patients than in normal subjects and is related to cognitive impairment.

"We should rethink MS as not just a disease of white matter demyelination," Dr. Rohit Bakshi from Brigham and Women's Hospital, Harvard Medical School, Boston, told Reuters Health. "Clearly there is gray matter involvement and tissue destruction occurring."

Dr. Bakshi and colleagues investigated thalamic volume and its relationship to cognitive function in 79 MS patients and 16 normal subjects. Their findings are published in the September 18th issue of Neurology.

Thalamic volume was 17.8 per cent lower in MS patients than in normal subjects, the authors report, and a significant 16.8 per cent difference persisted after adjusting for age, sex, and intracranial volume in each individual.

Thalamic atrophy in MS patients was associated with impairment on tests of processing speed/working memory and visuospatial memory, the researchers note. Thalamic fraction accounted for the greatest amount of variance in all models predicting neuropsychological test performance.

"We don't know enough yet to determine if patients (with thalamic atrophy) should be treated differently in terms of immunotherapeutic medications," Dr. Bakshi said. "However, our results suggest that when a patient is found to have thalamic atrophy on MRI scans, they should be carefully screened and tested for cognitive impairment, which could affect patient management, coping, and quality of life."

"Now more than ever we can see the importance of MRI technology towards the understanding of this complex challenging disease," Dr. Bakshi concluded.